Paige A. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paige A. Taylor has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Frasier Kry
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
6 shared publications David S. Followill
IROC Houston Quality Assurance Center, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas
3 shared publicationsNadia Hernandez
Department of Radiation Physics. The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publicationsPaola Alvarez
Department of Radiation Physics. The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications- Shannon Hartzell
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
3 shared publications Stephen F. Kry
Department of Radiation Physics The University of MD Anderson Cancer Center Houston Texas USA
3 shared publications
Latest Publications
- 19 June 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 223, 111649
Dose delivery accuracy of advanced radiotherapy: 30 years of end-to-end dosimetry audits
- 19 June 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 223, 111649
Dose delivery accuracy of advanced radiotherapy: 30 years of end-to-end dosimetry audits
- 17 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104215
Current Practice for Electronic Medical Device Management in Radiation Therapy
- 17 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104215
Current Practice for Electronic Medical Device Management in Radiation Therapy
- Open Access
- 2 January 2026
- Published by Elsevier in International Journal of Particle Therapy
- Vol. 19, 101297
Trends and Challenges: A 15-Year Review of Imaging and Radiation Oncology Core Anthropomorphic Phantom Audits for Proton Therapy
- 2 January 2026
- Published by Elsevier in International Journal of Particle Therapy
- Vol. 19, 101297
Open AccessTrends and Challenges: A 15-Year Review of Imaging and Radiation Oncology Core Anthropomorphic Phantom Audits for Proton Therapy
- Open Access
- 18 November 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (12) , e70390
Reference dosimetry data and machine performance comparison for tomotherapy delivery systems audited by IROC
The aim of this work was to compare the imaging and radiation oncology core (IROC) on‐site TomoTherapy dosimetry measurement results among institutions and generate a dataset of basic dosimetric properties for TomoTherapy units. Independent ion chamber measurements for nine TomoTherapy units were acquired by IROC physicists between 2008 and 2023. Measurements included percent depth dose (PDD) in a water tank and off axis factors (OAF) in a solid Polystyrene phantom. The independent measurements collected during the on‐site audits for each TomoTherapy system were compared to corresponding TomoTherapy TPS calculations from the institution to assess agreement. Numeric measurement values and comparative ratios are compiled and tabulated according to measurement type (i.e., PDD and OAF). The distribution of the measurements was evaluated, and the mean, standard deviation of the mean, and median values are reported. These data provide an independent guide describing the inherent performance characteristics of TomoTherapy units. Such data may serve as a secondary check for users wishing to verify their beam model commissioning and ongoing quality assurance efforts.
- 18 November 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (12) , e70390
Open AccessReference dosimetry data and machine performance comparison for tomotherapy delivery systems audited by IROC
The aim of this work was to compare the imaging and radiation oncology core (IROC) on‐site TomoTherapy dosimetry measurement results among institutions and generate a dataset of basic dosimetric properties for TomoTherapy units. Independent ion chamber measurements for nine TomoTherapy units were acquired by IROC physicists between 2008 and 2023. Measurements included percent depth dose (PDD) in a water tank and off axis factors (OAF) in a solid Polystyrene phantom. The independent measurements collected during the on‐site audits for each TomoTherapy system were compared to corresponding TomoTherapy TPS calculations from the institution to assess agreement. Numeric measurement values and comparative ratios are compiled and tabulated according to measurement type (i.e., PDD and OAF). The distribution of the measurements was evaluated, and the mean, standard deviation of the mean, and median values are reported. These data provide an independent guide describing the inherent performance characteristics of TomoTherapy units. Such data may serve as a secondary check for users wishing to verify their beam model commissioning and ongoing quality assurance efforts.
- Open Access
- 27 September 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (10) , 1-27
First experience with third‐party validations: A robust calibration and QA procedure for proton FLASH delivery
Background: Proton FLASH radiotherapy, delivering ultra‐high dose rates, shows promise in reducing normal tissue toxicity while maintaining tumor control. However, accurate dosimetry and quality assurance (QA) for FLASH remain challenging due to the extreme dose rates involved. Developing reliable calibration and QA procedures is crucial for advancing FLASH towards clinical implementation. Purpose: To present an effective routine calibration and QA procedure for proton FLASH delivery to ensure high‐quality dosimetry performance for preclinical and clinical delivery. Methods: A high temporospatial resolution strip ionization chamber array (SICA) detector was mounted to the treatment nozzle, which was calibrated using an Advanced Markus ion chamber (IC) under variable dose and ultra‐high dose rates. The calibration curve was used to monitor the delivery in real‐time. The maximum beam current was 215 nA at the isocenter at the highest energy of the cyclotron (250 MeV). Third‐party IROC (Imaging and Radiation Oncology Core) thermoluminescent dosimeters (TLDs) were requested to verify the accuracy and effectiveness of the calibration and validation procedure. A transmission field with a field size of 3 × 3 cm 2 was designed to deliver 2000 cGy doses with a field‐averaged dose rate varying from 36 to 76.5 Gy/s. Results: The entire calibration process took less than 10 minutes as part of routine daily QA. The calibration curve between the SICA detector and IC demonstrated an R ‐value of almost 1.00. The SICA detector measured each delivery, providing critical data for FLASH analysis, including field size, dose, delivery time, and dose rate. Based on real‐time dose and dose rate monitoring, the planned and delivered doses were within 1% accuracy according to third‐party TLD measurements. Conclusion: As demonstrated by IROC measurements, effective calibration and QA using a SICA detector for proton FLASH delivery can ensure high accuracy in real‐time dose and dose rate monitoring, paving the way for future clinical applications.
- 27 September 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (10) , 1-27
Open AccessFirst experience with third‐party validations: A robust calibration and QA procedure for proton FLASH delivery
Background: Proton FLASH radiotherapy, delivering ultra‐high dose rates, shows promise in reducing normal tissue toxicity while maintaining tumor control. However, accurate dosimetry and quality assurance (QA) for FLASH remain challenging due to the extreme dose rates involved. Developing reliable calibration and QA procedures is crucial for advancing FLASH towards clinical implementation. Purpose: To present an effective routine calibration and QA procedure for proton FLASH delivery to ensure high‐quality dosimetry performance for preclinical and clinical delivery. Methods: A high temporospatial resolution strip ionization chamber array (SICA) detector was mounted to the treatment nozzle, which was calibrated using an Advanced Markus ion chamber (IC) under variable dose and ultra‐high dose rates. The calibration curve was used to monitor the delivery in real‐time. The maximum beam current was 215 nA at the isocenter at the highest energy of the cyclotron (250 MeV). Third‐party IROC (Imaging and Radiation Oncology Core) thermoluminescent dosimeters (TLDs) were requested to verify the accuracy and effectiveness of the calibration and validation procedure. A transmission field with a field size of 3 × 3 cm 2 was designed to deliver 2000 cGy doses with a field‐averaged dose rate varying from 36 to 76.5 Gy/s. Results: The entire calibration process took less than 10 minutes as part of routine daily QA. The calibration curve between the SICA detector and IC demonstrated an R ‐value of almost 1.00. The SICA detector measured each delivery, providing critical data for FLASH analysis, including field size, dose, delivery time, and dose rate. Based on real‐time dose and dose rate monitoring, the planned and delivered doses were within 1% accuracy according to third‐party TLD measurements. Conclusion: As demonstrated by IROC measurements, effective calibration and QA using a SICA detector for proton FLASH delivery can ensure high accuracy in real‐time dose and dose rate monitoring, paving the way for future clinical applications.
- Open Access
NRG Oncology Liver Proton SBRT and Hypofractionated Radiation Therapy: Current Treatment Technical Assessment and Practice Patterns
Background/Objectives: Proton therapy delivers highly conformal doses to the target area without producing an exit dose, minimizing cumulative doses to healthy liver tissue. This study aims to evaluate current practices, challenges, and variations in the implementation of proton stereotactic body radiation therapy (SBRT) and hypofractionated therapy for liver malignancies, with the goal of providing a technical assessment to promote broader adoption and support future clinical trials. Methods and Materials: An extensive survey was conducted by NRG Oncology across North American proton treatment centers to assess the current practices of proton liver SBRT and hypofractionated therapy. The survey focused on key aspects, including patient selection, prescription and normal tissue constraints, simulation and motion management, treatment planning, quality assurance (QA), treatment delivery, and the use of image-guided radiation therapy (IGRT). Results: This survey captures the current practice patterns and status of proton SBRT and hypofractionated therapy in liver cancer treatment. Proton therapy is increasingly preferred for treating inoperable liver malignancies due to its ability to minimize healthy tissue exposure. However, the precision required for proton therapy presents challenges, particularly in managing uncertainties and target motion during high-dose fractions and short treatment courses. Survey findings revealed significant variability in clinical practices across centers, highlighting differences in motion management, dose fractionation schedules, and QA protocols. Conclusion: Proton SBRT and hypofractionated therapy offer significant potential for treating liver malignancies. A comprehensive approach involving precise patient selection, treatment planning, and QA is essential for ensuring safety and effectiveness. This survey provides valuable insights into current practices and challenges, offering a foundation for technical recommendations to optimize the use of proton therapy and guide future clinical trials.
Open AccessNRG Oncology Liver Proton SBRT and Hypofractionated Radiation Therapy: Current Treatment Technical Assessment and Practice Patterns
Background/Objectives: Proton therapy delivers highly conformal doses to the target area without producing an exit dose, minimizing cumulative doses to healthy liver tissue. This study aims to evaluate current practices, challenges, and variations in the implementation of proton stereotactic body radiation therapy (SBRT) and hypofractionated therapy for liver malignancies, with the goal of providing a technical assessment to promote broader adoption and support future clinical trials. Methods and Materials: An extensive survey was conducted by NRG Oncology across North American proton treatment centers to assess the current practices of proton liver SBRT and hypofractionated therapy. The survey focused on key aspects, including patient selection, prescription and normal tissue constraints, simulation and motion management, treatment planning, quality assurance (QA), treatment delivery, and the use of image-guided radiation therapy (IGRT). Results: This survey captures the current practice patterns and status of proton SBRT and hypofractionated therapy in liver cancer treatment. Proton therapy is increasingly preferred for treating inoperable liver malignancies due to its ability to minimize healthy tissue exposure. However, the precision required for proton therapy presents challenges, particularly in managing uncertainties and target motion during high-dose fractions and short treatment courses. Survey findings revealed significant variability in clinical practices across centers, highlighting differences in motion management, dose fractionation schedules, and QA protocols. Conclusion: Proton SBRT and hypofractionated therapy offer significant potential for treating liver malignancies. A comprehensive approach involving precise patient selection, treatment planning, and QA is essential for ensuring safety and effectiveness. This survey provides valuable insights into current practices and challenges, offering a foundation for technical recommendations to optimize the use of proton therapy and guide future clinical trials.
- Open Access
- 14 May 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (11) , 115001
OSLD nanoDot characterization for carbon radiotherapy dosimetry
Objective . This study characterized optically-stimulated luminescent dosimeter (OSLD) nanoDots for use in a therapeutic carbon beam using the Imaging and Radiation Oncology Core (IROC) framework for remote output verification. Approach . The absorbed dose correction factors for OSLD (fading, linearity, beam quality, angularity, and depletion), as defined by AAPM TG 191, were characterized for carbon beams. For the various correction factors, the effect of linear energy transfer (LET) was examined by characterizing in both a low and high LET setting. Main results . Fading was not statistically different between reference photons and carbon, nor between low and high LET beams; thus, the standard IROC-defined exponential function could be used to characterize fading. Dose linearity was characterized with a linear fit; while low and high LET carbon linearity was different, these differences were small and could be rolled into the uncertainty budget if using a single linearity correction. A linear fit between beam quality and dose-averaged LET was determined. The OSLD response at various angles of incidence was not statistically different, thus a correction factor need not be applied. There was a difference in depletion between low and high LET irradiations in a primary carbon beam, but this difference was small over the standard five readings. The largest uncertainty associated with the use of OSLDs in carbon was because of the k Q correction factor, with an uncertainty of 6.0%. The overall uncertainty budget was 6.3% for standard irradiation conditions. Significance . OSLD nanoDot response was characterized in a therapeutic carbon beam. The uncertainty was larger than for traditional photon applications. These findings enable the use of OSLDs for carbon absorbed dose measurements, but with less accuracy than conventional OSLD audit programs.
- 14 May 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (11) , 115001
Open AccessOSLD nanoDot characterization for carbon radiotherapy dosimetry
Objective . This study characterized optically-stimulated luminescent dosimeter (OSLD) nanoDots for use in a therapeutic carbon beam using the Imaging and Radiation Oncology Core (IROC) framework for remote output verification. Approach . The absorbed dose correction factors for OSLD (fading, linearity, beam quality, angularity, and depletion), as defined by AAPM TG 191, were characterized for carbon beams. For the various correction factors, the effect of linear energy transfer (LET) was examined by characterizing in both a low and high LET setting. Main results . Fading was not statistically different between reference photons and carbon, nor between low and high LET beams; thus, the standard IROC-defined exponential function could be used to characterize fading. Dose linearity was characterized with a linear fit; while low and high LET carbon linearity was different, these differences were small and could be rolled into the uncertainty budget if using a single linearity correction. A linear fit between beam quality and dose-averaged LET was determined. The OSLD response at various angles of incidence was not statistically different, thus a correction factor need not be applied. There was a difference in depletion between low and high LET irradiations in a primary carbon beam, but this difference was small over the standard five readings. The largest uncertainty associated with the use of OSLDs in carbon was because of the k Q correction factor, with an uncertainty of 6.0%. The overall uncertainty budget was 6.3% for standard irradiation conditions. Significance . OSLD nanoDot response was characterized in a therapeutic carbon beam. The uncertainty was larger than for traditional photon applications. These findings enable the use of OSLDs for carbon absorbed dose measurements, but with less accuracy than conventional OSLD audit programs.
- Open Access
- 25 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, 109494
Prioritizing clinical trial quality assurance for photons and protons: A failure modes and effects analysis (FMEA) comparison
- 25 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, 109494
Open AccessPrioritizing clinical trial quality assurance for photons and protons: A failure modes and effects analysis (FMEA) comparison
- 13 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 112 (4) , 1004-1011
The Value of On-Site Proton Audits
- 13 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 112 (4) , 1004-1011
The Value of On-Site Proton Audits